Brief: TScan Therapeutics Reports Full Year 2021 Financial Results And Highlights Key 2022 Priorities
09/03/2022 12:04
March 9 (Reuters) - TScan Therapeutics Inc TCRX.O :
* TSCAN THERAPEUTICS REPORTS FULL YEAR 2021 FINANCIAL
RESULTS AND
HIGHLIGHTS KEY 2022 PRIORITIES
* TSCAN THERAPEUTICS INC - PHASE 1 UMBRELLA TRIAL FOR LIQUID
TUMOR
PROGRAM TO INITIATE IN H1 2022; PRELIMINARY DATA EXPECTED IN H2
2022
Source text for Eikon: ID:nGNX2fCx5
Further company coverage: TCRX.O
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing